Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8266 to 8280 of 8899 results

  1. Difficult-to-treat scabies: oral ivermectin (ESUOM29)

    November 2024: This evidence summary has been withdrawn because licensed products are now available.

    Withdrawn advice

  2. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Withdrawn advice

  3. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Withdrawn advice

  4. Type 2 diabetes: empagliflozin (ESNM35)

    This evidence summary has been replaced by NICE technology appraisal guidance 336.

    Withdrawn advice

  5. Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  6. Relapsed and refractory multiple myeloma: pomalidomide (ESNM32)

    This evidence summary has been replaced by NICE technology appraisal guidance 338 [Replaced by NICE technology appraisal guidance 427]

    Withdrawn advice

  7. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  8. Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.

    Withdrawn advice

  9. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Withdrawn advice

  10. Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

    This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).

    Withdrawn advice

  11. Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  12. Induction of labour: misoprostol vaginal delivery system (ESNM38)

    We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.

    Withdrawn advice

  13. Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Withdrawn advice

  14. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Withdrawn advice

  15. Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice